Literature DB >> 6180075

Pharmacokinetics of human interferon-beta in monkeys.

J Hilfenhaus, H Damm, T Hofstaetter, R Mauler, H Ronneberger, E Weinmann.   

Abstract

Human fibroblast-derived interferon (HuIFN-beta) was administered to cynomolgus monkeys i.m. (2 x 10(5) iu/kg), i.v. (2 x 10(5) iu/kg) or intrathecally (3 x 10(5) iu/monkey) or given by a 3 hr i.v. infusion (2 x 10(5) iu/kg). One hr after intrathecal administration, interferon titers in the CSF were 1000-2000 iu/ml, and declined to less than 10 iu/ml during the first 24 hr. At the same time only minute amounts of HuIFN-beta were found in the sera of these animals. After i.m. administration, 5 iu/ml were found on average in the serum during the first 8 hr, with no interferon titer ever exceeding 10 iu/ml. No antiviral activity was found 24 hr after HuIFN-beta injection. HuIFN-beta injected i.v. resulted in serum interferon titers of approx. 300 iu/ml 30 min after administration, which then decreased to about 5 iu/ml during the first 8 hr 24 hr after injection no antiviral activity was detectable. Daily HuIFN-beta i.v. administrations over a period of four days did not affect the interferon clearance from the circulation. During HuIFN-beta infusion, constant HuIFN-beta titers of about 80 iu/ml were observed which then decreased during the following 5 hr to 2 iu/ml. The choice between a single i.v. injection, resulting in high serum titers for a few minutes, and a 3 hr infusion, resulting in an about fourfold lower but constant interferon level for over two hr, will depend on the mechanism of interferon action in vivo and on the question as to whether side effects can be diminished by infusion.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6180075     DOI: 10.1089/jir.1981.1.427

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  3 in total

1.  Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin.

Authors:  Toru Ishikawa; Satoshi Abe; Yuichi Kojima; Tomoe Sano; Akito Iwanaga; Kei-Ichi Seki; Terasu Honma; Toshiaki Yoshida; Mihoko Yamazaki; Takehito Sakai; Kazuyuki Tasaki; Yasushi Suzuki
Journal:  Exp Ther Med       Date:  2015-03-10       Impact factor: 2.447

2.  Interferon-beta in patients with low-grade astrocytomas--a phase I study.

Authors:  U Bogdahn; B Fleischer; J Hilfenhaus; H J Röthig; P Krauseneck; H G Mertens; H Przuntek
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

3.  Potentiation of enteral absorption of human interferon alpha and selective transfer into lymphatics in rats.

Authors:  H Yoshikawa; K Takada; Y Satoh; N Naruse; S Muranishi
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.